Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

39.99 +2.05 (+5.40%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Expert Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript
SRPT earnings call for the period ending March 31, 2023. 
Via The Motley Fool
Sarepta Therapeutics Earnings Preview
Via Benzinga
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating... 
Via Benzinga
Sarepta: More Drama Or Just More Noise?
Sarepta has a history at the FDA and recent reports indicate additional issues. What are the implications for accelerated approval and the long term prospects of Sarepta? 
Via Talk Markets
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
TD Cowen Maintains Outperform Rating for Sarepta Therapeutics: Here's What You Need To Know
Via Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
The major indexes retreated for most of the week on banking fears, 
Via Investor's Business Daily
Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness
Via Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics' FDA Adcomm Puts Some Risk, With Potential Approval: Analyst
Via Benzinga
FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy
Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy. 
Via Benzinga
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
According to a report, some staffers wanted to reject the highly watched drug. 
Via Investor's Business Daily
Why Is Merck (MRK) Stock Up Today?
Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda. 
Via InvestorPlace
Why Is BigBear.ai (BBAI) Stock Down 5% Today?
BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering. 
Via InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs. 
Via InvestorPlace
Why Sarepta Therapeutics Stock Is Tumbling Today
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
2 Top Growth Stocks That Could Soar This Spring
Exciting news on the way for both of these companies could send their stock prices screaming higher. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 4, 2023
Via Benzinga
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
3 Up-and-Coming Growth Stocks to Buy Right Now
These companies are small now but could grow much larger over time. 
Via The Motley Fool
Accelerated Approval For Gene Therapies - US Health Regulator Looks To Improve Process
The FDA seeks to optimize the development of gene therapies to help get accelerated approval of therapies. The US health regulator is looking to encourage using biomarkers, such as pulse and blood... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
A market rally is underway, but bank stocks kept tumbling. 
Via Investor's Business Daily
Why Baidu Shares Are Trading Higher By More Than 6%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Enzo Biochem, Inc. (NYSE: ENZ) gained 86.5% to $2.22 after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Sarepta Plunges As FDA Takes Surprise Turn; AdComm Meeting Set For Duchenne Gene Therapy
Via Benzinga
First Republic Bank, Blend Labs, Purple Innovation And Other Big Stocks Moving Lower On Friday
U.S. stocks traded lower, with the Dow Jones dropping more than 400 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.